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Abstract: Bisphosphonates and selective estrogen receptor modulators (SERMs) represent the two 
most important groups of medications taken orally and employed in osteoporosis treatment. Ef­
fectiveness of the therapy may be affected by poor patient adherence, in particular, due to the 
inconvenient dosing regimen of oral bisphosphonates. With this review we aimed to assess the 
effects that food, beverages, and dietary supplements consumed during treatment, along with the 
dosing regimens, may have on pharmacokinetics and pharmacodynamics of oral drugs employed 
in treating osteoporosis; we also aimed to shape the recommendations valuable for professional 
patients' counseling and education, to provide appropriate dosing regimens in order to improve 
adherence to the therapy. Food, beverages such as coffee, juices, and mineral water, as well as 
dietary supplements containing multivalent cations, e.g., calcium, magnesium, aluminium, iron, 
showed to have a deleterious effect on the bioavailability of all the investigated oral bisphosphonates, 
specifically alendronate, risedronate, ibandronate, minodronate, and etidronate. For risedronate, 
a delayed-release (DR) tablet was designed to solve the malabsorption problem in the presence of 
food, hence DR risedronate can be ingested following breakfast. For other oral bisphosphonates, 
the proper interval between drug and food, beverages, and dietary supplements intake should be 
maintained to minimize the risk of interactions. The effect of food on pharmacokinetic parameters of 
selective estrogen receptor modulators (SERMs) was found to be clinically irrelevant.
Keywords: bisphosphonates; SERMs; interaction; food; supplements; bioavailability; meal; coffee; 
juice; mineral water
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1. Introduction
Being a chronic skeletal disease that leads to a gradual bone density loss and increased 
bone fragility, as well as susceptibility to fractures, osteoporosis remains a significant 
reduced life quality risk factor in older patients. At least one in three women and one in
five men in their 50s are estimated to experience osteoporotic fracture in their lifetime, often 
followed by further serious health consequences. Due to the progressive population aging, 
the problem of treating osteoporosis is more actual than ever. To provide the effective 
therapy with the two most important groups of drugs used in osteoporosis treatment, 
namely bisphosphonates and selective estrogen receptor modulators (SERMs), their proper 
administration in relation to food/m eal time should be followed. Poor patient's adherence 
to drug administration regimens is considered one of the main problems that may affect the 
efficacy of the therapy, as it depends on the correct medications administration schemes and 
persistence in applying the treatment [1]. It is estimated that 50% of all patients discontinue 
therapy with oral bisphosphonates within 1 to 2 years from onset [2], or even earlier, before
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any clinical effect can be seen [3] . Moreover, even one-third of the patients may administer 
their medications improperly [4]. It is impossible to indicate one reason for poor adherence, 
as the problem is multifaceted. Yeam et al. [5]  recognized up to 24 factors that can affect 
medications adherence among patients with osteoporosis. However, in many studies, top 
two issues reported by patients as the cause of non-adherence to osteoporosis treatment 
seem to predominate. The first issue is the poor motivation to take the drugs, due to the 
lack of disease symptoms and hence no clinical signs of drug effectiveness. The second 
problem includes inconvenient dosing regimen of oral bisphosphonates, especially the 
need to fast before, and to stay upright after the administration [2- 4]. In response to the 
problem of non-adherence, Cornelissen et al. [6] concluded recently that patient education, 
supervision, counselling, and shared decision making on changing the dosing regimen, 
may improve both persistence and compliance, and consequently, also the effectiveness of 
osteoporosis treatment.
Another general problem is that patients, physicians, pharmacists and dieticians may 
underestimate the impact of food and dosing regimen on drugs effectiveness [7]. A recent 
study in a district general hospital suggests that healthcare professionals shall be reminded 
about proper dosing regimens for oral bisphosphonates. In an observation period of 6 
months, Wilcock et al. [8 ] indicated that among 398 doses of alendronate or risedronate 
administered to patients in a hospital setting, half of the doses were given less than 30 min 
before breakfast, that is at the time when food may dramatically reduce bisphosphonates 
absorption. Although the main limitation of the study was the assumption around the 
exact time of breakfast, these results should be taken into consideration.
In elderly patients, the greater emphasis should be put on food-drug interactions due 
to the polypharmacy, and self-medication with dietary and nutritional supplements and 
OTC drugs (including herbal medicines) [9]. Thus, this review focused on the effects that 
consumption of food, beverages, and dietary supplements, as well as dosing regimens, may 
have on pharmacokinetics and pharmacodynamics of oral drugs employed in treating os­
teoporosis. This is the first such comprehensive review that brings together the information 
not only about bisphosphonates, but also about selective estrogen modulators, with the 
emphasis on oral forms of the drugs. Some valuable recommendations, for professional pa­
tients' counselling, summarizing the intake of the osteoporosis drugs with relation to food, 
and presenting how to avoid the potential interactions, are also included in the review.
2. Materials and Methods
To collect information on interactions between food and medications for osteoporo­
sis, the authors, namely AW and PP, performed a literature research in the Medline (via 
PubMed) and Embase databases, covering reports from 1986 to 2021. The following key­
words and phrases were applied in the searching process: drugs names ("alendronate", 
"risedronate", "ibandronate", "minodronate", "etidronate", "raloxifene", "bazedoxifene") 
in combinations with "food ", "food-drug interaction", "m eal", "breakfast", "bioavail­
ability", "ju ice", "coffee", "tea", "m ilk", "iron", "alum inum ", "calcium ", "m agnesium ", 
"alcohol", and "m ineral w ater". Furthermore, other resources such as drugs.com, Mi- 
cromedex, AHFS, and UpToDate, were also researched, as well as characterization charts 
of particular medicinal products. Additional publications were found by checking the 
reference lists.
Initially, 155 articles were tracked. After removing 27 duplicates and performing 
the first evaluation, 78 articles reporting or investigating the effect of meals, beverages, 
dietary supplements, and dosing regimen on pharmacokinetics and pharmacodynamics of 
drugs used in oral osteoporosis treatment were considered to be included. No restrictions 
for study design, participants' characteristics, or sample size were made. 35 reviews, 
two in vitro studies, and nine studies performed on animals were subsequently excluded. 
Finally, 32 original studies remained included and are discussed in this review. A flowchart 
of the searching strategy is presented in Figure 1.
Figure 1. Searching strategy flowchart.
3. Results and Discussion
3.1. Oral Bisphosphonates
Various guidelines on managing osteoporosis recommend oral bisphosphonates as the 
first-choice drugs [10- 13], widely prescribed in postmenopausal osteoporosis, secondary 
osteoporosis, and male osteoporosis. Bisphosphonates are often referred to as "antire- 
sorptive drugs", due to their mechanism of action, as they inhibit osteoclast-mediated 
bone resorption [14]. A recent meta-analysis confirmed bisphosphonates' use to decrease 
the risk of both vertebral and non-vertebral osteoporotic fractures [15]. The treatment 
becomes effective relatively early, namely within 6-12 months from starting the therapy, 
and the results tend to prolong [16]. Despite its established effectiveness, therapy with oral 
bisphosphonates may still be found challenging, due to the overall low bisphosphonates 
bioavailability, likely gastrointestinal side effects, such as heartburn, irritated esopha­
gus, nausea, gastric ulcers, etc., but also the potential interactions with food and dietary 
supplements [14,16].
3.1.1. Chemical Characterization of the Bisphosphonates
All bisphosphonates are the analogs of pyrophosphate, containing two phosphate 
groups linked by carbon atom (P-C-P), instead of an oxygen atom [17]. Additionally, 
as presented in Figure 2, each bisphosphonate has two side chains bound to the central 
carbon atom.
Figure 2. Chemical structures of bisphosphonates discussed in the review.
Of the drugs discussed in this review, only etidronate does not contain nitrogen atom, 
as it is representative of the oldest, first-generation of bisphosphonates. The addition 
of nitrogen, either as a constituent of the amine group (alendronate and ibandronate) or 
heterocyclic ring (in risedronate and minodronate) is known to enhance the antiresorptive 
activity [17].
The Biopharmaceutical Classification System (BCS) assigns each pharmacologically ac­
tive compound to one of four classes, based on its water solubility and intestinal membrane 
permeability, since these parameters determine the rate and extent of drug absorption [18]. 
Bisphosphonates, as the highly soluble and hardly permeable compounds, belong to the III 
class of BCS. High water solubility (in other words—very low lipophilicity) of bisphospho­
nates is due to the presence of hydrophilic phosphate groups. These groups are negatively 
charged in physiological pH, hence the bisphosphonate compound is completely ionized in 
the intestine lumen. Ionized and hydrophilic compounds penetrate lipid membranes with 
great difficulty. That explains both the low permeability and very low oral bioavailability 
of bisphosphonates, which is known to range from 0.6 to 3%, depending on the drug [19].
3.1.2. Interaction with Di- and Trivalent Cations
Although the overall effect of calcium, or vitamin D alone, on the reduction of fracture 
risk remains unclear [13,20], the supplementation of both substances is currently recom­
mended for patients at high risk of calcium and vitamin D insufficiency, and in those 
treated for osteoporosis [21]. In consequence, concomitant use of oral bisphosphonates and 
calcium preparations is widespread.
Oral bisphosphonates are chelating agents that form salts with multivalent cations 
present in food, dietary supplements, drugs (e.g., antacids), and mineral water [14]. These 
salts are insoluble at pH > 5, and as such, bisphosphonate cannot be absorbed in the intes­
tine [22]. In characterization charts of oral bisphosphonates, the recommended minimum 
time interval between their ingesting and the intake of vitamins, dietary supplements or 
antacids, containing multivalent cations such as calcium, aluminum, magnesium, and 
chromium, varies from at least 30 min to 2 h, depending on the drug [23- 27], while at least 
last 2 h for iron preparations [28]. For oral bisphosphonates taken once a week, or once a 
month, it may be even justified to refrain from administering calcium preparations on the 
same day as a bisphosphonate.
To improve the patients' understanding of co-treatment rules, but also compliance, 
fixed-combination packs of bisphosphonates and calcium carbonate were designed and 
tested. In a cross-over study in 164 postmenopausal women, Ringe et al. [29] revealed that 
use of the combination pack containing one tablet of risedronate 35 mg and six tablets 
of calcium carbonate 1250 mg (500 mg of elemental calcium) for one week, significantly 
improved patients' comprehension of dosing instructions, when compared to separate 
packaging (80% vs. 70%, respectively). In some countries such fixed-combinations packs 
are already registered, e.g., for alendronate (APO-Alendronate Plus D3 and calcium), or 
risedronate (Actonel Combi).
3.1.3. Problem with Water Type
The results of preclinical studies indicated that alendronate and risedronate absorption 
may decrease with the increasing concentration of calcium in mineral water used for drug 
administering [30,31]. As instructed by prescribing guidelines, oral bisphosphonates are 
recommended to be taken with tap water, to minimize the risk of malabsorption caused 
by calcium and other cations present in mineral and spring waters. However, tap water 
can be alkaline as well. Pellegrini et al. [32] reported that in some regions of Italy (e.g., 
Rome or Milan) calcium content of tap water might be even up to 100 times higher than in 
some commercially available bottled waters (100-110 m g /L  vs. 1-2 m g /L , respectively). 
Morr et al. [33] obtained similar results after examining tap waters from cities in the USA 
and Canada, where reportedly, calcium content varied from 1 to 135 m g /L . For compar­
ison, spring waters were found to contain lower calcium concentrations (approximately
21.8 m g/L ), and mineral waters in general showed higher calcium content (an average 
of 208 m g/L). Due to the lack of experimental evidence, neither specific nor approximate 
maximum calcium intake that would not alter bisphosphonates absorption has been es­
tablished. For that reason, Azoulay et al. [34] emphasized the need to check the mineral 
content of both bottled and tap waters before administering bisphosphonates. Moreover, 
Morr et al. [33] observed that filtering tap water with a home filter system may remove on 
average 89% of calcium, hence proposed this alternative for patients living in regions with 
the high calcium content of tap water. Such approach may be thus recommended as one of 
the elements of preventing the decrease in the effectiveness of bisphosphonates therapy.
3.1.4. Alendronate
Alendronate (syn. alendronic acid, alendronate sodium) is available in tablet (Fosamax, 
Ostemax), effervescent tablet (Binosto), and oral solution (Fosamax) forms, taken daily or 
weekly. The same doses of different alendronate formulations are bioequivalent [23,35]. 
Additionally, in 2012, the oral jelly formulation (Bonalon) has been approved in Japan, 
to reduce the risk of choking and to prevent gastrointestinal side effects [36]. In some 
countries combination of alendronate in the same tablet with vitamin D (Fosamax Plus) is 
registered as well.
Oral bioavailability of alendronate under fasting conditions is 0.64% in women (for 
dosage range 5 -70  mg), and 0.59% in men (for dose 10 mg); in the presence of food and 
beverages further decrease is observed [23,37].
Gertz et al. [22] conducted series of open-label, randomized, cross-over trials to 
establish the most optimal regimen for alendronate administration regarding food and 
beverages. In the first study of 10 post-menopausal women, a single dose of 20 mg 
alendronate tablet was administered after an overnight fast, in three dosing regimens: (1) 2 h 
before breakfast—reference regimen, (2) 1 h before breakfast, or (3) 30 min before breakfast; 
with or without calcium carbonate supplement (containing 1000 mg of elemental calcium). 
The detailed composition of the breakfast was described in Table 1—Set No 1. In the second 
study of 49 post-menopausal women, a single dose of 10 mg alendronate tablet was taken 
after an overnight fast, in five dosing regimens: (1) 2 h before breakfast—reference regimen, 
(2) 1 h before breakfast, (3) 30 min before breakfast, (4) immediately after breakfast, or 
(5) 2 h after breakfast (Table 1, Set No 2). Results of both studies were comparable and 
found that the administration of alendronate 30 min and 1 h before breakfast reduced its 
bioavailability approximately by 40%, relative to the reference regimen. Moreover, the 
second study revealed that ingesting alendronate concomitantly with breakfast, or even 
2 h after the meal, may drastically impair drug absorption (by 85-90% ). Adding calcium 
supplement to breakfast in the first study did not cause an additional decrease in absorption 
when compared to ingesting the meal alone. In the third study of 40 post-menopausal 
women, a single dose of 10 mg alendronate tablet was taken, followed an overnight fast, 2 h 
before breakfast, with (1) 240 mL of tap water— reference regimen, (2) black unsweetened 
coffee, or (3) orange juice. Coffee and orange juice were found to significantly reduce 
alendronate absorption (by 60% for both beverages) relative to administration with water. 
What is worth noting, the study is probably the only example, describing the interactions 
between any bisphosphonate and coffee and fruit juice, thus the important results should 
be further continued to draw more reliable conclusions.
Wagener et al. [38] assessed whether the ingestion of alendronate during the day, 
with 1 h fast before a meal, could be an effective dosing regimen. After 8 weeks of study, 
significant changes in biochemical markers of bone turnover, namely osteocalcin, alkaline 
phosphatase, and dipeptidyl peptidase, were observed, suggesting that despite a non­
optimal dosing regimen, the efficacy of treatment was maintained.
Table 1. Detailed composition of the meals used in the studies described in this review.




2 pieces of white toast, jelly/marmalade 
(20 g), 1 fried egg, 2 strips of bacon, 
and orange juice (250 mL)
70.6 g of carbohydrates, 6.3 g 





1 piece of white toast, 2 pats of butter, 2 
strips of bacon, 2 fried eggs, hash brown 
potatoes (2-4 oz), 
and whole milk (240 mL).
40.3 g of carbohydrates, 29 g of 






Smoked turkey, vegetable and beef soup 
with crackers, and whole wheat bread 
with lettuce (283 g), tossed salad (142 g) 
with light salad dressing (12 g), 
mayonnaise (15 mL), 2 canned peach 
halves, and skimmed milk (283 g)
104 g of carbohydrates, 19 g of 





2 slices of white toast, 2 pats of butter, 2 
slices of bacon, hash brown potatoes 
(57 g), 2 eggs fried in butter, 
and whole milk (226 g)
50 g of carbohydrates, 46 g of 





baked chicken breast (113 g), 1 baked 
potato, light gravy (28 g), 1 pat of 
margarine, 0.5 cup of apple sauce, 0.5 cup 
of carrot rounds, 1 peanut butter cookie, 
and lemonade (283 g)
103 g of carbohydrates, 16 g of 






chicken drumstick, fried egg, 
hamburger, and milk
30% of carbohydrates, 55% of 
fat, 15% of protein
Approx. 
900 kcal [40]
The impact of food on the bioavailability of alendronate was investigated for effer­
vescent tablet formulation as well. A study of 119 healthy women revealed that taking 
70 mg alendronate 15 min before standard breakfast may decrease its bioavailability by 
approximately 50%, when compared to administering 4 h before a meal [35].
Interestingly, a recent prospective case-control study [2] suggested that administering 
alendronate after breakfast, despite the existing evidence of the impaired drug absorption 
for this regimen, may have positive influence on a patient's persistence and adherence, 
and hence improve the efficacy of treatment. Park et al. [2] compared 1-year persistence 
and therapy effectiveness in patients taking 5 mg alendronate tablet in two regimens: (1) 
according to the guidelines. i.e., 30 min before breakfast, and (2) after breakfast. After 
1 year, the medication possession ratio (MPR), measured as the sum of administration days 
divided by 365 days, was significantly higher in patients taking alendronate after breakfast, 
relative to the recommended regimen (0.71 vs. 0.66, respectively), which indicate enhanced 
persistence and adherence. Additionally, significant improvement in lumbar and hip T- 
scores was observed in both groups, together with no significant differences between the 
groups, which suggests the therapy effectiveness to be similar for both treatment regimens.
3.1.5. Risedronate
Risedronate (syn. risedronic acid, risedronate sodium) is available in two formulations: 
immediate-release (IR) tablets (Actonel, Risendros) taken daily, once a week or once a month, 
and delayed-release (DR) tablets (Atelvia) taken once a week.
Immediate-Release (IR) Tablets
The mean oral bioavailability of the 30 mg IR tablet of risedronate is 0.63%, when 
administered while fasting, whereas the concomitant intake of food decreases it further [24]. 
Mitchell et al. [39] conducted a randomized, parallel study in 127 healthy volunteers, to 
compare four different timing regimens for risedronate administration: (1) after night 
fasting, 4 h before lunch (Table 1, Set No 3) that was the reference regimen, (2) after night 
fasting, 1 h before a high-fat breakfast (Table 1, Set No 4), (3) after night fasting, 30 min 
before a high-fat breakfast (Table 1, Set No 4), (4) 2 h after a standard dinner (Table 1, Set 
No 5). After administering a single dose of 30 mg risedronate IR tablets in each group, 
pharmacokinetic parameters such as AUC 0 - M and Cm a x  were measured. Risedronate, both 
taken 30 min before breakfast (group 3), and 2 h after dinner (group 4), showed the lowest 
extend of absorption, when compared to the reference regimen; AUC and C m a x  were 
reduced by 56 and 32% in group 3; and by 52 and 75% in group 4, respectively. To compare, 
when risedronate was taken 1 h before breakfast (group 2), AUC and C m a x  were reduced by 
32 and 14%, respectively. Mitchell et al. concluded that although the most optimal dosing 
regimen for risedronate in IR tablets is 1 h before breakfast, a flexible-dosing approach may 
be considered, since dosing either 30 min before breakfast or 2 h after dinner resulted in a 
similar extend of risedronate absorption.
Ogura et al. [12] performed a similar study in 12 healthy Japanese volunteers, ran­
domly assigned to administer 5 mg of IR risedronate (1) under fasting conditions, without 
breakfast— a reference regimen, (2) 30 min before breakfast, (3) 30 min after breakfast, and 
(4) 3 h after breakfast. Breakfast contained 200 mg of elemental calcium. To compare the 
level of risedronate absorption in different regimens, such pharmacokinetic parameters 
as AUC 0 - 2 4 , C m a x , tm a x , and t1 / 2  were measured. Administering risedronate 30 min after 
breakfast (3) caused the highest decrease in AUC0 - 2 4  and C m a x  (both by 94%), and the high­
est increase in tm a x  and t1 / 2  (by 62 and 39%, respectively), when compared to the reference 
regimen. Contrastingly, administration 30 min before breakfast decreased AUC 0 - 2 4  by 63%, 
and C m a x  by 26%, hence Ogura et al. recommended this regimen as the most optimal for 
Japanese patients. However, it should be emphasized that in this study administration 
60 min before breakfast was not investigated.
In two studies of a total number of 1582 postmenopausal women with osteoporo­
sis, Kendler et al. [41] assessed the influence of dosing regimen on risedronate efficacy 
measured by lumbar spine bone mineral density (BMD). Risedronate IR tablets in a daily 
dose of 5 mg were administered (1) under fasted conditions, at least 30 min before the first 
meal of the day, or (2) between meals, at least 2 h from a meal or 30 min before bedtime. 
Both studies provided similar observations. Both dosing regimens resulted in a signifi­
cant increase from the baseline in lumbar spine BMD, however response to risedronate 
was smaller for flexible dosing. In the first study, an increase in lumbar spine BMD after 
6 months was 2.9% for (1) regimen and 1.5% for (2) regimen, and in the second study after 
12 months, 4.4 and 3.2% respectively. Kendler et al. [41] suggested that minor response 
to treatment in the flexible dosing group may be due to less than optimal risedronate 
absorption, when taken between meals, or poorer compliance to this regimen, especially in 
certain geographic regions.
Agrawal et al. [42] also studied the efficacy of the flexible-dosing approach in a 
randomized, double-blind trial in 60 residents of the nursing home (NH). 31 of participants 
were weekly administered 30 mg of risedronate in IR tablets, between meals but at least 
2 h from a meal, and 29 received placebo. The effect of the treatment was measured by 
the changes in the serum levels of bone turnover markers (e.g., bone-specific alkaline 
phosphatise— BSAP). Risedronate administered in-between-meal schedule significantly 
reduced serum BSAP after 6 weeks of study relative to the control group, but this effect 
was not maintained after 12 weeks. Agrawal et al. [42] provided possible reasons for 
the ineffectiveness of flexible-dosing regimen in NH residents, such as delayed gastric 
emptying in the elderly, leading to impaired absorption of risedronate, when taken between
meals, or high prevalence of vitamin D insufficiency that may contribute to the increase of 
bone turnover.
Delayed-Release (DR) Tablets
Enteric-coated DR risedronate formulation was developed with the addition of ethylene- 
diaminetetraacetic acid (EDTA), the chelator of metal ions. As a result, di- and trivalent 
cations in food may be preferentially bound by EDTA instead of risedronate, which elimi­
nates the need for fasting and improves risedronate bioavailability, when compared with 
IR formulation [14]. For example, 35 mg of risedronate in DR tablet taken after a high-fat 
breakfast was found to have similar bioavailability as the same dose in IR tablet adminis­
tered 4 h before a meal, and 2-4-fold greater bioavailability than the IR tablet administered 
30 min before breakfast [25].
In a recent randomized, double-blind, placebo-controlled study of 68 healthy post­
menopausal women, Fukase et al. [43] investigated the influence of dosing regimens on 
pharmacokinetic and pharmacodynamic parameters of risedronate in DR tablets. A single 
dose of 37.5 mg was administered (1) under fasting conditions— a reference regimen, (2) 
30 min before a meal, (3) immediately after a meal, or (4) 30 min after a meal. The meal 
consisted of 492 kcal and contained 4% of fat. W hen compared to fasting conditions, 
taking risedronate DR tablets immediately after a meal resulted in a significant decrease 
of AUC0-m and Cmax (by 58 and 69%, respectively). However, pharmacokinetic and 
pharmacodynamic profiles for regimen (2), (3), and (4) were comparable, hence Fukase et al. 
suggested that DR formulation can be taken independently from meals.
Similar results were obtained in a cross-over pharmacokinetic study, where adminis­
tration of DR tablet with high-fat breakfast resulted in a 30% decrease of bioavailability, 
compared to fasting state [25]. However, it should be noted that when DR tablets are taken 
on an empty stomach, an 8-9%  increase in gastrointestinal adverse events may occur [25]. 
A possible solution to this problem could comprise administering risedronate after dinner. 
In a separate study, taking DR tablets in that regimen improved bioavailability by 87%, 
compared to the administration with breakfast. Nevertheless, the data for the safety and 
efficacy of taking risedronate DR tablets at bedtime is scarce [25].
In a randomized 2-year study of postmenopausal women with osteoporosis, 
McClung et al. [44,45] compared the efficacy of weekly administered 35 mg risedronate 
in DR tablets in two dosing regimens: at least 30 min before breakfast (BB), or following 
breakfast (FB) with 5 mg IR tablets taken daily while fasting. The effectiveness of the 
treatment was measured by changes in lumbar spine BMD. After 1 year of the study [44], 
the mean percent changes in lumbar spine BMD for 767 women were 3.4% in the 35 mg 
DR BB group, 3.3% in the 35 mg DR FB group, and 3.1% in the 5 mg IR daily group. After 
2 years of treatment [45], the mean percent changes in lumbar spine BMD for 722 women 
were higher in all groups: 5.4% in the DR BB weekly group, 5.5% in the DR FB weekly 
group, and 4.4% in the IR daily group. McClung et al. concluded that weekly treatment 
with risedronate 35 mg DR is at least as effective as daily administered risedronate 5 mg IR, 
and DR formulation can be taken either before or after breakfast with similar efficacy.
On the contrary, a recent randomized phase II/III double-blind study [46] in Japanese 
patients with involutional osteoporosis revealed that the effectiveness of risedronate DR 
therapy may significantly differ, depending upon dosing regimen and formulation. Two 
doses of DR risedronate—25 and 37.5 mg were administered monthly for 1 year: (1) under 
fasting conditions, (2) concomitantly with breakfast, or (3) 30 min after breakfast. The 
efficacy of treatment was measured by changes in lumbar spine BMD and compared 
with daily administered IR 2.5 mg risedronate. At the end of the study, for DR 25 mg, 
percentage changes in lumbar spine BMD for regimens (1), (2), (3) were as follows: 3.82, 
3.36,3.93%, for DR 37.5 mg: 4.81,4.11,4.36% , respectively, and for IR 2.5 mg: 5.07%. Results 
indicated that risedronate ingestion immediately with breakfast is the least effective, and 
the non-inferiority of treatment with IR and DR formulations cannot be declared.
Although most of the concerned studies indicate that DR formulation can be ad­
ministered while eating, without significant changes in bioavailability and efficacy, still 
the intake of supplements containing di- and trivalent cations should be delayed. In a 
cross-over study on 101 postmenopausal women, the bioavailability of a single 35 mg 
dose of risedronate DR tablets was evaluated, when taken following breakfast, with or 
without the supplement containing 600 mg of elemental calcium and 400 IU of vitamin 
D. Concomitant intake of risedronate and calcium-containing supplement reduced drug 
absorption by 38% [25].
3.1.6. Ibandronate
Ibandronate (syn. ibandronic acid, ibandronate sodium) for oral use is available in 
tablets (Bonviva, Bondronat), taken at monthly intervals. The mean oral bioavailability is 
approximately 0.6% for a dose of 2.5 mg [26].
In a pharmacokinetic study, the bioavailability of ibandronate was found to be dramat­
ically reduced (by 90%), when 150 mg tablet was ingested concomitantly with a standard 
breakfast, relative to the fasting state [26]. Ingesting ibandronate 2 h after a standard meal 
or 30 min before breakfast significantly reduced the bioavailability as well (by 75% and 30%, 
respectively) [47]. No meaningful reduction in ibandronate bioavailability was observed 
for administration at least 60 min before breakfast [26,47].
In single-centre clinical trials, Nakai et al. [48] investigated the influence of fasting 
intervals on ibandronate bioavailability measured as AUC0-m. In the first study, 24 healthy 
postmenopausal women were administered 2.5 mg ibandronate tablets 30 or 60 min before 
breakfast. Measured AUC0-m were 1.12 ±  0.95 and 1.40 ±  0.77 ng-h/m L, respectively. In the 
second study, 24 healthy men and postmenopausal women were given 50 mg ibandronate 
tablets. Measured AUC0-m values were 11.1 ±  23.5 ng-h/m L for 30-min fasting interval, 
and 16.0 ±  15.6 ng-h/m L for 60-min fasting interval. Nakai et al. concluded that shortening 
the fasting period from 60 to 30 min may result in lower ibandronate bioavailability, and 
hence recommended delaying food intake for 1 h after drug administration.
In a 48-week, multi-centre, open-label study, Tanko et al. [49] examined whether 
different dosing regimens may influence the effectiveness of ibandronate treatment, mea­
sured by percentage changes in lumbar spine BMD from baseline. 184 postmenopausal 
women were randomly assigned to administer 2.5 mg ibandronate tablets 30 or 60 min 
before their standard breakfast. At the end of the study, significant increases in lumbar 
spine BMD were observed in both groups, however, in a group where a 60-min fasting 
interval was maintained, the mean change in the lumbar spine BMD was higher than 
in a group with a 30-min fasting interval (4.95 vs. 3.07%, respectively). Taking it into 
consideration, Tanko et al. suggested that fasting interval after ingesting ibandronate can 
be reduced to 30 min, however increasing drug dose may be required to maintain the 
efficacy of treatment.
3.1.7. Minodronate
Minodronate (syn. minodronic acid) is approved for the treatment of osteoporosis 
in Japan. Among available oral bisphosphonates, it is the strongest inhibitor of bone 
resorption, hence it can be administered once a month [50]. Bioavailability of minodronate 
after oral administration was calculated to be 1.21% [51].
In an open-label study of 12 healthy volunteers, Zhou et al. [40] investigated the 
influence of meals on minodronate absorption. A single dose of 4 mg was administered 
while fasting or 30 min before a high-fat breakfast (Table 1, Set No 6) consisted of 400 mg 
of elemental calcium. Taking minodronate 30 min before breakfast reduced AUC0 -m and 
Cmax by 72 and 55%, respectively, and increased tmax from 0.75 to 2.15 h relative to fasted 
conditions. These results indicate a necessity to administer minodronate while fasting.
3.1.8. Etidronate
Etidronate (syn. etidronic acid, etidronate disodium) is available in tablets (Didronel) 
taken in 90-days cycles: daily for 14 days, followed by calcium supplementation for the 
remaining 76 days. Although etidronate is no longer recommended in American College of 
Physicians guidelines for the treatment of osteoporosis [13], and it is not FDA-approved for 
this indication as well, in some countries etidronate use is still considered as the second-line 
therapy for osteoporosis [52].
The oral bioavailability of etidronate is approximately 3% [27]. A single-dose study 
on 10 healthy volunteers revealed that administering 400 mg etidronate during breakfast 
may reduce drug absorption to zero [53].
In a retrospective study of 110 patients with osteoporosis, Cook et al. [54] assessed the 
influence of etidronate dosing regimen on treatment effectiveness, measured by changes 
in BMD. Patients were administered etidronate (1) after waking up, (2) at bedtime, or (3) 
during the day, and maintained 2 h fasting intervals before and after drug ingestion. After 
approximately 2.6 years of study, no significant differences in percentage change in BMD 
were found between the three groups, indicating that the dosing regimen of etidronate 
does not affect the efficacy of therapy.
Nevertheless, in another study of 70 patients treated with etidronate, Ryan et al. [55] 
revealed that drug ingestion during the day, even with 2 h fast before and after dosing, 
may still result in significantly impaired treatment response (lower percentage changes in 
BMD), when compared to administration in the early morning or late evening.
3.2. Selective Estrogen Receptor Modulators (SERMs)
Selective estrogen receptor modulators (SERMs) act as agonists on estrogen receptors 
in bone— modulate skeletal homeostasis by diminishing the activity of osteoclasts and 
maintaining the function of osteoblasts [56] . SERMs decrease bone remodelling, prevent 
bone loss by increasing bone mineral density [56] and are recommended as the most 
beneficial in younger postmenopausal women with mild and moderate osteoporosis [57]. 
The most common side effects of treatment with SERMs are hot flashes, leg cramps, and an 
increased risk of deep vein thrombosis [56,57].
The core structure of SERMs is based on 17ß-estradiol template. Chemical structures 





Figure 3. Chemical structures of SERMs discussed in the review.
Both raloxifene and bazedoxifene belong to the II class of BCS— as lipophilic com­
pounds they are hardly soluble in water and easily permeable by membrane cells. Low
water solubility, together with the first-pass metabolism are the main factors negatively 
affecting oral bioavailability of these drugs [58].
3.2.1. Raloxifene
Raloxifene is available in tablets (Evista), taken once daily. On average 60% of an oral 
dose is rapidly absorbed from the gastrointestinal tract, however, due to the extensive 
first-pass hepatic metabolism, absolute oral bioavailability is only 2% [59]. The presence 
of food does not influence raloxifene pharmacokinetics. Concomitant ingestion with a 
high-fat meal increased AUC and Cm a x  by 16 and 28%, respectively, though these changes 
were considered insignificant [60].
3.2.2. Bazedoxifene
Bazedoxifene is available in tablets taken daily, both alone (Conbriza) and in combina­
tion with conjugated estrogens (Duavee). The absolute oral bioavailability of bazedoxifene 
is on average 6% [61].
To examine the impact of food on bazedoxifene pharmacokinetic parameters, 
McKeand et al. [62] administered a single 10 mg bazedoxifene tablet to 84 healthy post­
menopausal women, either while fasting, or 10 min before a high-fat breakfast. Concomi­
tant intake with a meal reduced bazedoxifene Cm a x  by 35%, but this change was considered 
insignificant; AUC for both dosing regimens were comparable.
Other studies revealed that the administration of bazedoxifene with food may even 
slightly enhance drug absorption. After taking a 20 mg tablet with a high-fat meal, AUC 
and C m a x  increased by 28 and 22%, respectively, and after ingestion with a medium-fat 
meal, by 35 and 42%, correspondingly. However, these changes were found clinically 
irrelevant, and it was concluded that bazedoxifene may be taken regardless of food [61].
The influence of food was also investigated for bazedoxifene combined with conju­
gated estrogens. In a crossover study, 23 postmenopausal women were administered a 
single 20 m g/0.625 mg tablet either under fasting conditions, or with a high-fat, high-calorie 
meal. Ingestion with a meal increased AUC 0 _ M by 25%, while Cm a x  remained unchanged, 
suggesting that combined preparation can be administered without regard to meals as 
well [63].
3.3. Recomendations
Table 2 below presents the summary of the most important data and recommendations 
for appropriate intake of drugs employed in treating osteoporosis with regard to food. 
Knowledge on the subject, with special emphasis on oral bisphosphonates, is critical to 
educate patients professionally and effectively, which is the key intervention to enhance 
adherence to oral osteoporosis treatment.
Table 2. The summary of recommendations for appropriate intake of drugs employed in treating osteoporosis with regard 
to food.






should be taken at least 30 min
before breakfast
should be taken at least 30 min
before vitam ins, mineral
supplem ents, or antacids high
in calcium , alum inum , or
m agnesium
should be taken at least 2  h 
before iron preparations 
sw allow ing with coffee and 
ju ice should be avoided
tablets should be swallowed with 
a full glass of tap water 
effervescent tablets should be 
dissolved in a half a glass of 
tap water
the oral solution should be taken 
w ith at least a quarter a glass of 
tap water
je lly  can be adm inistered 
w ithout water
should be taken w hile standing 
or sitting in an upright position 
lying down for at least 30 min 
after adm inistration should 
be avoided
[2,22,23,35,37,38]
im m ediate-release (IR ) tablets
daily, w eekly 
or m onthly
should be taken at least 30 min 
before breakfast 
the flexible-dosing approach 
m ight be considered 
calcium, magnesium , and 
alum inum  preparations should 
be adm inistered at a different 
tim e of the day 
should be taken at least 2  h 
before iron preparations
should be swallowed w ith a full 
glass of tap water 
should be taken w hile standing 
or sitting in an upright position 
lying down for at least 30 min 
after adm inistration should 
be avoided
[12,24,39,41,42]
delayed-release (D R) tablets Weekly
should be taken im m ediately 
follow ing breakfast 
adm inistration at bedtim e 
m ight be considered 
calcium , m agnesium , and 
alum inum  preparations should 
be adm inistered at a different 
tim e of the day 
should be taken at least 2  h 
before iron preparations
should be swallowed w ith at 
least half a glass of tap water 
should be taken w hile standing 
or sitting in an upright position 
lying down for at least 30 min 
after adm inistration should 
be avoided
[14,25,43- 46]
Ibandronate tablets M onthly
should be taken at least 1  h 
before breakfast 
should be taken at least 1  h 
before vitam ins, mineral 
supplem ents, or antacids high 
in calcium , alum inum , or 
m agnesium
should be taken at least 2  h 
before iron preparations
should be swallowed w ith a full 
glass of tap water 
should be taken w hile standing 
or sitting in an upright position 
lying down for at least 60 min 
after adm inistration should 
be avoided
[26,47- 49 ]
M inodronate tablets M onthly should be taken at least 30 min before breakfast
should be swallowed w ith a tap 
water
should be taken w hile standing 
or sitting in an upright position 
lying down for at least 30 min 
after adm inistration should 
be avoided
[40 ]
Etidronate tablets daily for 14 days, 
in 90-days cycles
should be taken at least 2  h 
before food (especially 
high-calcium  products), early 
in the m orning, or at bedtim e 
should be taken at least 2  h 
before vitam ins, mineral 
supplem ents, or antacids high 
in calcium , m agnesium , 
alum inum , iron
should be swallowed w ith a full
glass of tap water
should be taken w hile standing
or sitting in an upright position





can be taken irrespectively 
of food [60]
Bazedoxifene tablets Daily




A proper regimen of administration for medications used in oral osteoporosis therapy 
is crucial not only for the treatment effectiveness but also for minimizing the risk of 
adverse events and hence improving the patient's quality of life. For the first-choice drugs, 
namely oral bisphosphonates, their combined administration with food, beverages, and 
dietary supplements containing multivalent cations, showed to have a deleterious effect on 
the bioavailability, and treatment efficacy. Changing drug formulation to delayed-release
tablets may partially solve this problem, however more studies are needed. On the contrary, 
the effect of food on pharmacokinetic parameters of selective estrogen receptor modulators 
(SERMs) is clinically irrelevant. It is also worth noting that the data on the interactions 
of osteoporosis drugs with the individual food components is scarce, while the results of 
the existing studies suggests the importance of the problem. Thus, in our opinion, further 
in-depth studies are highly recommended, the results of which may complete the current 
strategy in enhancing the effectiveness of osteoporosis treatment.
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